Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Q3 2025 value amounting to $199.1 million.

  • Catalyst Pharmaceuticals' Non-Current Assets fell 1453.27% to $199.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $863.3 million, marking a year-over-year decrease of 986.85%. This contributed to the annual value of $227.8 million for FY2024, which is 916.44% down from last year.
  • As of Q3 2025, Catalyst Pharmaceuticals' Non-Current Assets stood at $199.1 million, which was down 1453.27% from $213.2 million recorded in Q2 2025.
  • Catalyst Pharmaceuticals' Non-Current Assets' 5-year high stood at $250.8 million during Q4 2023, with a 5-year trough of $24.8 million in Q2 2022.
  • Its 5-year average for Non-Current Assets is $144.3 million, with a median of $202.9 million in 2023.
  • Its Non-Current Assets has fluctuated over the past 5 years, first surged by 1312985.9% in 2021, then plummeted by 2774.99% in 2022.
  • Quarter analysis of 5 years shows Catalyst Pharmaceuticals' Non-Current Assets stood at $27.7 million in 2021, then surged by 98.05% to $54.8 million in 2022, then skyrocketed by 357.44% to $250.8 million in 2023, then fell by 9.16% to $227.8 million in 2024, then decreased by 12.58% to $199.1 million in 2025.
  • Its Non-Current Assets stands at $199.1 million for Q3 2025, versus $213.2 million for Q2 2025 and $223.2 million for Q1 2025.